Company Overview and News
NTPM Holdings Bhd (Sept 24, 54 sen) Maintain buy with a lower target price of 62 sen: NTPM Holdings Bhd’s core net profit of RM6.6 million for the first quarter ended July 31, 2018 (1QFY19) was below expectations, after reaching only 14% of our forecast. The negative deviation could be attributed to lower-than-expected sales from its personal care product segment and our overly optimistic cost assumptions.
KUALA LUMPUR (Sep 21): Based on corporate announcements and news flow today, stocks in focus for Monday (Sep 24) may include the following: Malaysia Airports Holdings Bhd, United Plantations Bhd, Utusan Melayu (Malaysia) Bhd, Telekom Malaysia Bhd, Binasat Communications Bhd, KESM Industries Bhd, NTPM Holdings Bhd, Country Heights Holdings Bhd and MNRB Holdings Bhd.
UPBMF 5066 5088 2089 5014 9334 5754 4863 5738 6459 MYPRY MYTEF 1902
NTPM Holdings Bhd (June 26, 53.5 sen) Maintain buy with a target price of 65 sen: NTPM Holdings Bhd’s core net profit for financial year 2018 (FY18) of RM35 million (-33% year-on-year [y-o-y]) was below expectations, at just 88% of our full-year forecast. The negative deviation could be attributed to the softer-than-expected sales in the personal care segment and our overly optimistic margin assumptions.
KUALA LUMPUR (June 26): Shares in NTPM Holdings Bhd retreated as much as 9.4% in the morning session today, after the company reported an 86.8% year-on-year decline in net profit to RM1.18 million for the fourth financial quarter ended April 30, 2018 (4QFY18).
KUALA LUMPUR: JF Apex Research expects Kelington Group Bhd , Gabungan AQRS Bhd , NTPM Holdings Bhd , Serba Dinamik Holdings Bhd and Hiap Teck Venture Bhd to be among the stocks to watch on Tuesday.
5226 5072 5066 0151
KUALA LUMPUR (June 25): Based on corporate announcements and news flow today, stocks in focus for Tuesday (June 256) may include the following: Serba Dinamik Holdings Bhd, Grand-Flo Bhd, Euro Holdings Bhd, Malaysia Building Society Bhd, MB World Group Bhd, D&O Green Technologies Bhd, Kelington Group Bhd, Gabungan AQRS Bhd and NTPM Holdings Bhd.
5226 7208 5066 5681 1171 0151
KUALA LUMPUR (June 25): Higher raw material cost continued to drag down the net profit of NTPM Holdings Bhd, falling 86.8% to RM1.18 million for the fourth financial quarter ended April 30, 2018 (4QFY18) from RM8.95 million a year ago. This resulted in a lower earnings per share of 0.11 sen for 4QFY18 from 0.8 sen for 4QFY17.
KUALA LUMPUR: JF Apex Research expects Hai-O Enterprise Bhd , Gamuda Bhd , Pesona Metro Holdings Bhd , Astino Bhd and NTPM Holdings Bhd are among the stocks to watch on Monday.
7668 5066 8311
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...